EGFR and non-small cell lung carcinoma: Based on these results, we suggest that NSCLC harboring uncommon EGFR mutations should not be treated as a single disease; rather, we should determine an appropriate TKI (and appropriate drug concentrations as reported recently [36]) for each mutation subtype.